Rockefeller Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.44M Sell
113,057
-60,381
-35% -$4.44M 0.01% 804
2026
Q2
$11.1M Hold
173,438
– – 0.02% 693
2026
Q1
$8.35M Hold
173,438
– – 0.01% 739
2025
Q4
$7.15M Hold
173,438
– – 0.01% 769
2025
Q3
$6.73M Buy
+173,438
New +$5.63M 0.01% 743
2023
Q1
– Sell
-5,750
Closed -$86K – 3009
2022
Q4
$86K Hold
5,750
– – ﹤0.01% 2102
2022
Q3
$73K Hold
5,750
– – ﹤0.01% 2162
2022
Q2
$55K Hold
5,750
– – ﹤0.01% 2233
2022
Q1
$57K Hold
5,750
– – ﹤0.01% 2239
2021
Q4
$67K Buy
5,750
+5,000
+667% +$61.4K ﹤0.01% 2087
2021
Q3
$8K Hold
750
– – ﹤0.01% 2995
2021
Q2
$10K Hold
750
– – ﹤0.01% 2776
2021
Q1
$13K Hold
750
– – ﹤0.01% 2481
2020
Q4
$13K Hold
750
– – ﹤0.01% 2154
2020
Q3
$11K Hold
750
– – ﹤0.01% 1987
2020
Q2
$19K Buy
+750
New +$15.7K ﹤0.01% 1694

Other funds holding KNSA

Rockefeller Capital Management's KNSA Position: Q3 2026 in Review

Rockefeller Capital Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 35% in Q3 2026, selling an estimated $4.44M and leaving 113,057 shares worth $8.44M. The position accounts for 0.01% of the portfolio, ranked #804.

Rockefeller Capital Management first reported a position in KNSA in Q2 2020 and has held it in 16 quarters since. The position peaked at $11.1M in Q2 2026. 305 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

  • Rockefeller Capital Management held 113,057 shares of Kiniksa Pharmaceuticals worth $8.44M as of Q3 2026.
  • Rockefeller Capital Management sold 60,381 Kiniksa Pharmaceuticals shares in Q3 2026, an estimated $4.44M.
  • Kiniksa Pharmaceuticals made up 0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #804 holding.
  • Rockefeller Capital Management first reported a position in Kiniksa Pharmaceuticals in Q2 2020 and has held it in 16 quarters since.
  • Rockefeller Capital Management's Kiniksa Pharmaceuticals position peaked at $11.1M in Q2 2026.
  • 305 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.